Major Biotechs Have Short Sellers on the Run
The September 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 121
Akcea and Ionis Pharma Win Big in Midstage Cardiovascular Disease Study
Akcea and Ionis Pharmaceuticals shares made a solid gain on Monday after the companies announced positive top-line data for a midstage trial in patients with established cardiovascular disease and elevated levels of lipoprotein(a).
Kodiak Sciences Announces Potential Pricing for IPO
Clinical-stage biopharmaceutical company Kodiak Sciences expects to price 9 million shares for an initial public company valued up to more than $155 million.
What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments
There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large…
Jefferies Biotech Growth Picks Have Big Upside Potential
Jefferies highlights the firm's top growth stocks to buy each week, and recently four top biotech stocks made the cut. They all make good sense now, and all have outstanding upside potential.
Why Amarin Shares Are Exploding
Amarin shares absolutely skyrocketed on Monday after the company announced topline results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT. Needless to say, the results were very positive.
Alzheimer’s, Dementia Will Hit Minority Groups Hardest
Changing U.S. demographics will change the proportion of Americans who suffer from Alzheimer's and other dementia-related diseases. The diseases are forecast to hit Hispanics and African Americans hardest.
What the FDA Has to Say About Acadia Pharma’s Parkinson’s Treatment
Acadia Pharmaceuticals shares popped after the company announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson’s disease psychosis.
Why JPMorgan Is So Bullish on Novavax
Friday's trading session showed Novavax on the leaderboard after an analyst upgrade from JPMorgan.
Can GTx Make It Past This Enobosarm Study?
GTx shares were absolutely crushed on Friday after the company announced results from its mid-stage trial in post-menopausal women with stress urinary incontinence.
Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential
A series of new Stifel research reports focus on three biotech companies that have upcoming clinical data that could prove to be huge.
Elanco Explodes Into the Market in IPO
Eli Lilly spin-off Elanco Animal Health made a strong entrance to the market on Thursday.
How Adverum Bio Is Winning With FDA Update
Adverum Biotechnologies shares made a handy gain on Thursday after the company announced a key update from the FDA.
Should AbbVie Be More Concerned About Its California Case for Humira?
AbbVie shares took a dip on Wednesday after it was announced that the pharma giant would be facing a lawsuit from the California Department of Insurance in regards to allegedy kickbacks given to health…
Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results
Clovis shares might not be showing it now, but the company is facing some heat from the SEC over charges of misleading investors about the company’s developmental lung cancer drug.